Medicure Inc. (OTCMKTS:MCUJF) will post its quarterly earnings results after the market closes on Tuesday, November 21st. Analysts expect Medicure to post earnings of $0.18 per share for the quarter.

Shares of Medicure Inc. (MCUJF) opened at $6.45 on Friday. Medicure Inc. has a 52-week low of $4.64 and a 52-week high of $7.96. The firm has a market capitalization of $102.66, a price-to-earnings ratio of 6.82 and a beta of 1.11. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.43 and a current ratio of 0.65.

ILLEGAL ACTIVITY NOTICE: “Medicure Inc. (MCUJF) to Release Earnings on Tuesday” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/19/medicure-inc-mcujf-to-release-earnings-on-tuesday.html.

Separately, Zacks Investment Research downgraded Medicure from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th.

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Stock Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related stocks with our FREE daily email newsletter.